MAG gene variation and cortical gray matter volume in first episode schizophrenia

Brain Imaging and Behavior

Volumn 2, Issue 2, 2008, Pages 117-122

  Voineskos, Aristotle N ^a   Lang, Donna J ^b   Zai, Gwyneth ^a   Bulgin, Natalie ^a   Shaikh, Sajid ^a   Su, Wayne ^b   Kopala, Lili C ^b   MacEwan, G William ^b   Thornton, Allen E ^c   Smith, Geoffrey N ^b   Austin, Jehannine C ^b   Honer, William G ^b   Kennedy, James L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Cortical gray matter; Genetics; Magnetic resonance imaging; Myelin; Oligodendrocytes; Schizophrenia

Indexed keywords

MYELIN ASSOCIATED GLYCOPROTEIN;

ADULT; ARTICLE; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; GRAY MATTER; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER;

EID: 77949652567     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-008-9023-6     Document Type: Article

References (37)

1. Aberg, K., Saetre, P., Jareborg, N., & Jazin, E. (2006a). Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 103, 7482-7487.
2. Aberg, K., Saetre, P., Jareborg, N., & Jazin, E. (2006b). Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 103(19), 7482-7487.
3. Chua, S. E., Cheung, C., Cheung, V., Tsang, J. T., Chen, E. Y., Wong, J. C., et al. (2007). Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophrenia Research, 89(1-3), 12-21.
4. Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., et al. (2003). White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Archives of General Psychiatry, 60, 443-456.
5. Dwork, A. J., Mancevski, B., & Rosoklija, G. (2007). White matter and cognitive function in schizophrenia. Int J Neuropsychopharmacol, 10(4), 513-536.
6. Fannon, D., Chitnis, X., Doku, V., Tennakoon, L., O'Ceallaigh, S., Soni, W., et al. (2000). Features of structural brain abnormality detected in first-episode psychosis. American Journal of Psychiatry, 157(11), 1829-1834.
7. Flynn, S. W., Lang, D. J., Mackay, A. L., Goghari, V. M., Vavasour, I. M., Whittall, K. P., et al. (2003). Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Molecular Psychiatry, 8, 811-820.
8. Hakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., et al. (2001a). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 98, 4746-4751.
9. Hakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., et al. (2001b). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 98(8), 4746-4751.
10. Haroutunian, V., & Davis, K. L. (2007). Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia. International Journal of Neuropsychopharmacology, 10(4), 499-502.
11. Haroutunian, V., Katsel, P., Dracheva, S., Stewart, D. G., & Davis, K. L. (2007). Variations in oligodendrocyte-related gene expression across multiple cortical regions: Implications for the pathophysiology of schizophrenia. International Journal of Neuropsychopharmacology, 10(4), 565-573.
12. Hoenig, J., & Heisey, D. (2001). The abuse of power: The pervasive fallacy of power calculations for data analysis. American Statistician, 55, 19-24.
13. Hof, P. R., Haroutunian, V., Friedrich, V. L., Byne, W., Buitron, C., Perl, D. P., et al. (2003a). Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biological Psychiatry, 53, 1075-1085.
14. Hof, P. R., Haroutunian, V., Friedrich Jr., V. L., Byne, W., Buitron, C., Perl, D. P., et al. (2003b). Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biological Psychiatry, 53(12), 1075-1085.
15. Katsel, P., Davis, K. L., Gorman, J. M., & Haroutunian, V. (2005a). Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophrenia Research, 77, 241-252.
16. Katsel, P., Davis, K. L., Gorman, J. M., & Haroutunian, V. (2005b). Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophrenia Research, 77(2-3), 241-252.
17. Katsel, P., Davis, K. L., & Haroutunian, V. (2005c). Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophrenia Research, 79, 157-173.
18. Katsel, P., Davis, K. L., & Haroutunian, V. (2005d). Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study. Schizophrenia Research, 79(2-3), 157-173.
19. Keshavan, M. S., Haas, G. L., Kahn, C. E., Aguilar, E., Dick, E. L., Schooler, N. R., et al. (1998). Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? Journal of Psychiatric Research, 32(3-4), 161-167.
20. Lenth, R. (2001). Some practical guidelines for effective sample size determination. American Statistician, 55, 187-193.
21. Lieberman, J. A., Tollefson, G. D., Charles, C., Zipursky, R., Sharma, T., Kahn, R. S., et al. (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62(4), 361-370.
22. Lim, K. O., Tew, W., Kushner, M., Chow, K., Matsumoto, B., & DeLisi, L. E. (1996). Cortical gray matter volume deficit in patients with first-episode schizophrenia. American Journal of Psychiatry, 153(12), 1548-1553.
23. McCullumsmith, R. E., Gupta, D., Beneyto, M., Kreger, E., Haroutunian, V., Davis, K. L., et al. (2007). Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophrenia Research, 90(1-3), 15-27.
24. Mitelman, S. A., Brickman, A. M., Shihabuddin, L., Newmark, R. E., Hazlett, E. A., Haznedar, M. M., et al. (2007). A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia. Neuroimage, 37(2), 449-462.
25. Morgan, K. D., Dazzan, P., Orr, K., Hutchinson, G., Chitnis, X., Suckling, J., et al. (2007). Grey matter abnormalities in first-episode schizophrenia and affective psychosis. British Journal of Psychiatry, 191, s111-s116.
26. Peirce, T. R., Bray, N. J., Williams, N. M., Norton, N., Moskvina, V., Preece, A., et al. (2006). Convergent evidence for 2′, 3′-cyclic nucleotide 3′-phosphodiesterase as a possible susceptibility gene for schizophrenia. Archives of General Psychiatry, 63(1), 18-24.
27. Qin, W., Gao, J., Xing, Q., Yang, J., Qian, X., Li, X., et al. (2005). A family-based association study of PLP1 and schizophrenia. Neuroscience Letters, 375, 207-210.
28. Robinson, D. G., Woerner, M. G., Napolitano, B., Patel, R. C., Levy, S. M., Gunduz-Bruce, H., et al. (2006). Randomized comparison of olanzapine versus risperidone for the treatment of first episode schizophrenia: 4 month outcomes. American Journal of Psychiatry, 163(12), 2096-2102.
29. Scherk, H., & Falkai, P. (2006). Effects of antipsychotics on brain structure. Current Opinion in Psychiatry, 19, 145-150.
30. Steen, R. G., Mull, C., McClure, R., Hamer, R. M., & Lieberman, J. A. (2006). Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry, 188, 510-518.
31. Tkachev, D., Mimmack, M. L., Ryan, M. M., Wayland, M., Freeman, T., Jones, P. B., et al. (2003). Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet, 362(9386), 798-805.
32. Uranova, N., Orlovskaya, D., Vikhreva, O., Zimina, I., Kolomeets, N., Vostrikov, V., et al. (2001). Electron microscopy of oligodendroglia in severe mental illness. Brain Research Bulletin, 55(5), 597-610.
33. Wan, C., Yang, Y., Feng, G., Gu, N., Liu, H., Zhu, S., et al. (2005a). Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neuroscience Letters, 388, 126-131.
34. Wan, C., Yang, Y., Feng, G., Gu, N., Liu, H., Zhu, S., et al. (2005b). Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neuroscience Letters, 388(3), 126-131.
35. Yang, Y. F., Qin, W., Shugart, Y. Y., He, G., Liu, X. M., Zhou, J., et al. (2005a). Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. Schizophrenia Research, 75, 11-19.
36. Yang, Y. F., Qin, W., Shugart, Y. Y., He, G., Liu, X. M., Zhou, J., et al. (2005a). Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. Schizophrenia Research, 75(1), 11-19.
37. Zai, G., King, N., Wong, G. W., Barr, C. L., & Kennedy, J. L. (2005). Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia. European Neuropsychopharmacology, 15, 347-352.